Last reviewed · How we verify

Randomization of Propofol or Dexmedetomidine

Children's Hospital Los Angeles · FDA-approved active Small molecule

This is a clinical trial comparing two sedative agents: propofol (a GABA-A receptor agonist) and dexmedetomidine (an alpha-2 adrenergic agonist) for sedation in pediatric patients.

This is a clinical trial comparing two sedative agents: propofol (a GABA-A receptor agonist) and dexmedetomidine (an alpha-2 adrenergic agonist) for sedation in pediatric patients. Used for Sedation in pediatric patients (comparative trial).

At a glance

Generic nameRandomization of Propofol or Dexmedetomidine
SponsorChildren's Hospital Los Angeles
Drug classSedative/Hypnotic agents
TargetGABA-A receptor (propofol); Alpha-2 adrenergic receptor (dexmedetomidine)
ModalitySmall molecule
Therapeutic areaAnesthesia/Sedation
PhaseFDA-approved

Mechanism of action

Propofol enhances inhibitory GABAergic neurotransmission in the central nervous system to produce rapid sedation and anesthesia. Dexmedetomidine selectively activates alpha-2 adrenergic receptors in the brain and spinal cord to produce sedation and analgesia with preserved airway reflexes. This trial randomizes patients to receive one agent or the other to compare efficacy and safety profiles in children.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: